Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The front desk was so welcoming even assisting me with parking
Study: Triple-Hormone-Receptor Agonist Retatrutide for Obesity Journal: New England Journal of Medicine (NEJM) ClinicalTrials ID: NCT04881760 View Full Study Retatrutide is a glucagon, GLP-1, and GIP (triple hormone) receptor agonist being investigated to treat obesity
Pharm Lett/Presc Lett
For patients who prefer online access, telehealth alternatives offer similar GLP-1 medications starting at $297/month with free consultations and home delivery
GIP receptor activation enhances insulin response, improves fat metabolism, and contributes to the additional weight loss seen in head-to-head trials
US$ 20.38
US$ 26.22
US$ 29.48
US$ 24.15
US$ 26.70
US$ 28.02
